.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Steven M. Horwitz, MD

Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

December 18th 2024

Steven Horwitz, MD, presents the final results of the Phase 2 PRIMO trial, highlighting the efficacy and safety of duvelisib as a promising treatment option for relapsed/refractory peripheral T-cell lymphoma, with insights into overall response rates, progression-free survival, and adverse event management.

Dr. Horwitz Discusses the Results of the ECHELON-2 Study

December 13th 2018

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma

October 5th 2016

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

Dr. Horwitz on the Future of CHOP for T-Cell Lymphoma

April 4th 2015

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the CHOP regiment for t-cell lymphoma.

Dr. Horwitz on the Challenges With T-Cell Lymphoma

February 25th 2015

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the challenges oncologists face with T-cell lymphoma.